Palatin Technologies Presents at the American Psychiatric Association (APA)

[PR Newswire] – CRANBURY, N.J., May 6, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of more

View todays social media effects on PTN

View the latest stocks trending across Twitter. Click to view dashboard

See who Palatin is hiring next, click here to view